Naslov: | Addition of 2-(ethylamino)acetonitrile group to nitroxoline results in significantly improved anti-tumor activity in vitro and in vivo |
---|
Avtorji: | ID Mitrović, Ana (Avtor) ID Sosič, Izidor (Avtor) ID Kos, Špela (Avtor) ID Lampreht Tratar, Urša (Avtor) ID Breznik, Barbara (Avtor) ID Kranjc Brezar, Simona (Avtor) ID Mirković, Bojana (Avtor) ID Gobec, Stanislav (Avtor) ID Lah Turnšek, Tamara (Avtor) ID Čemažar, Maja (Avtor) ID Serša, Gregor (Avtor) ID Kos, Janko (Avtor) |
Datoteke: | PDF - Predstavitvena datoteka, prenos (4,30 MB) MD5: D122E245A831A4E6A8A2A7DE4054FBC4
URL - Izvorni URL, za dostop obiščite https://doi.org/10.18632/oncotarget.19296
|
---|
Jezik: | Angleški jezik |
---|
Tipologija: | 1.01 - Izvirni znanstveni članek |
---|
Organizacija: | NIB - Nacionalni inštitut za biologijo
|
---|
Povzetek: | Lysosomal cysteine peptidase cathepsin B, involved in multiple processes associated with tumor progression, is validated as a target for anti-cancer therapy. Nitroxoline, a known antimicrobial agent, is a potent and selective inhibitor of cathepsin B, hence reducing tumor progression in vitro and in vivo. In order to further improve its anti-cancer properties we developed a number of derivatives using structure-based chemical synthesis. Of these, the 7-aminomethylated derivative (compound 17) exhibited significantly improved kinetic properties over nitroxoline, inhibiting cathepsin B endopeptidase activity selectively. In the present study, we have evaluated its anti-cancer properties. It was more effective than nitroxoline in reducing tumor cell invasion and migration, as determined in vitro on two-dimensional cell models and tumor spheroids, under either endpoint or real time conditions. Moreover, it exhibited improved action over nitroxoline in impairing tumor growth in vivo in LPB mouse fibrosarcoma tumors in C57Bl/6 mice. Taken together, the addition of a 2-(ethylamino)acetonitrile group to nitroxoline at position 7 significantly improves its pharmacological characteristics and its potential for use as an anti-cancer drug. |
---|
Ključne besede: | nitroxoline derivative, cathepsin B, inhibition, tumor invasion, cell migration |
---|
Status publikacije: | Objavljeno |
---|
Verzija publikacije: | Objavljena publikacija |
---|
Datum objave: | 17.07.2017 |
---|
Leto izida: | 2017 |
---|
Št. strani: | str. 59136-59147 |
---|
Številčenje: | Vol. 8, no. 35 |
---|
PID: | 20.500.12556/DiRROS-19722 ![Povezava se odpre v novem oknu Novo okno](teme/dirros/img/NovoOkno.png) |
---|
UDK: | 577.2 |
---|
ISSN pri članku: | 1949-2553 |
---|
DOI: | 10.18632/oncotarget.19296 ![Povezava se odpre v novem oknu Novo okno](teme/dirros/img/NovoOkno.png) |
---|
COBISS.SI-ID: | 4360305 ![Povezava se odpre v novem oknu Novo okno](teme/dirros/img/NovoOkno.png) |
---|
Opomba: | Nasl. z nasl. zaslona;
Opis vira z dne 9. 8. 2017;
|
---|
Datum objave v DiRROS: | 26.07.2024 |
---|
Število ogledov: | 196 |
---|
Število prenosov: | 170 |
---|
Metapodatki: | ![Izvoz v DC-RDF DC-RDF](teme/dirros/img/icon_dc_rdf.gif) |
---|
:
|
Kopiraj citat |
---|
| | | Objavi na: | ![Bookmark and Share](teme/dirros/img/addtoany.png) |
---|
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |